Drug Trial Radar · NCT06359899
A Study to Evaluate the Efficacy, Safety and Tolerability of Oral AK0901 in Children With ADHD
Last checked: Nov 20, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
55
Actual
Start
May 28, 2024
Primary completion
Jan 6, 2025
Study completion Jan 11, 2025
Sponsor
- Lead sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 11, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a Phase 3, multicenter, dose-optimized, double-blind, randomized, placebo-controlled study designed to evaluate the efficacy, safety, and tolerability of oral AK0901 capsules in children 6 to 12 years old with Attention Deficit Hyperactivity Disorder(ADHD).
Conditions
- ADHD
Interventions
AK0901 capsuleDrug
Active Substance: AK0901, Pharmaceutical Form: Capsule, Route of Administration: Oral
PlaceboDrug
Active Substance: Placebo, Pharmaceutical Form: Capsule, Route of Administration: Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the efficacy of AK0901 compared to placebo in children 6 to 12 years old with ADHD.Time frame: From Baseline (Pre-dose on Day 1) to week 3
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Beijing anding hospital capital medical university
Beijing, Beijing Municipality, China
Peking university sixth hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.